← SynDRA
ALOSETRON
SynDRA canonical compound SYN0003772 — structure-anchored drug synonym record
| Clinical phase | Withdrawn |
| Approval status | Approved · Rx/OTC |
| Primary target(s) | HTR3A |
| Mechanism of action | Serotonin receptor antagonist |
All known targets
Mechanisms of action (all sources)
- Serotonin receptor antagonist
- HTR3A ANTAGONIST
- Serotonin 3a (5-HT3a) receptor antagonist
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ADRA2C
- CYP2C9
- CYP3A4
- HTR2A
- HTR2C
- CYP2B6
- CYP2D6
- CYP2C19
- MLNR
- MMP1
- MMP9
- ACHE
- MC4R
- MPG
- NEIL1
- NPY1R
- NPY2R
- MC5R
- MBD4
- MC3R
- NR3C1
- MAPK3
- MAPK14
- MAPK1
- MAOA
- LCK
- HTR7
- HTR6
- HTR1A
- HRH2
- HRH1
- HMGCR
- NR1I2
- OGG1
- GPR35
- OPRD1
- USP1
- UNG
- TDP1
- TDG
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ARNT
- CP1A2
- CP2C9
- CP2CJ
- CP2D6
- CP3A4
- CP3A7
- SC5A7
- TACC3
- UBP1
Drug classes
- Gastrointestinal Agents
- Neurotransmitter Agents
- Serotonin Agents
- Serotonin Antagonists
- Serotonin 3 Receptor Antagonists
- Serotonin-3 Receptor Antagonist
ATC classes
- A03A · DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
Cross-references
Synonyms
- ALOSETRON HYDROCHLORIDE
- LOTRONEX
- Lotronex
- alosetron hydrochloride
- alosetron HCl
- alosetron monohydrochloride
- GR68755
- A03AE01
- Lotrpnex
- Alosetron HCl
- Alosetron hydrochloride [USAN]
- Alosetron monohydrochloride
- GR 68755
- GR 68755X
- GR-68755C
- Alosetron (INN)
- Alosetron [INN:BAN]
- Alosetron hydrochloride (USAN)
- Lotronex (TN)
- Lotrpnex (TN)
- GR-68755
- CHEBI:253342
- alosetronum
- RefChem:58090
- DTXCID4024278
- ALOSETRON [INN]
- MLS001401464
- NCGC00167528-01
- SMR000469211
- UNII-13Z9HTH115
- ALOSETRON [MI]
- ALOSETRON [VANDF]
- SCHEMBL631
- ALOSETRON [WHO-DD]
- cid_60758
- SCHEMBL148316
- GTPL2296
- orb1705182
Reported adverse events
- Abdominal discomfort
- Abdominal pain
- Anxiety
- Arrhythmia
- Burning sensation
- Constipation
- Flatulence
- Headache
- Malaise
- Nausea
- Rash
- Tachyarrhythmia
Look up ALOSETRON in the interactive SynDRA portal →